Thursday, May 2, 2019

Anika Therapeutics reports Q1 EPS 31c, consensus 19c

Reports Q1 revenue $24.7M, consensus $21.88M. Q1 Adjusted EBITDA was $8.3M vs. $1.2M last year.
at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.